基于机制的治疗方法在遗传性神经发育障碍中的应用前景。
The Way Forward for Mechanism-Based Therapeutics in Genetically Defined Neurodevelopmental Disorders.
机构信息
Translational Neuroscience Center, F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Clin Pharmacol Ther. 2018 Oct;104(4):603-606. doi: 10.1002/cpt.1181. Epub 2018 Aug 12.
Abstract
Rare genetically defined neurodevelopmental disorders with increased risk of autism have recently become an entry point for autism-related drug discovery. Through exploration of downstream effects of the pathological mutations, specific mechanistic pathways have been identified as dysregulated. The identification of shared mechanisms across forms of autism opens the door for the development of novel "mechanism-based therapeutics." However, confidence in the therapeutic mechanism does not diminish the need for well-designed clinical trials.
摘要
最近，具有自闭症风险增加的罕见遗传性神经发育障碍已成为自闭症相关药物发现的切入点。通过探索病理性突变的下游效应，已经确定了特定的失调机制途径。自闭症不同形式之间存在共同机制的发现为开发新型“基于机制的疗法”打开了大门。然而，对治疗机制的信心并没有降低对精心设计的临床试验的需求。
相似文献
1
The Way Forward for Mechanism-Based Therapeutics in Genetically Defined Neurodevelopmental Disorders.基于机制的治疗方法在遗传性神经发育障碍中的应用前景。
Clin Pharmacol Ther. 2018 Oct;104(4):603-606. doi: 10.1002/cpt.1181. Epub 2018 Aug 12.
2
Treating a Child With Mental Illness.儿童精神疾病的治疗。
Clin Pharmacol Ther. 2018 Oct;104(4):592-594. doi: 10.1002/cpt.1182.
3
Emerging pharmacotherapies for neurodevelopmental disorders.神经发育障碍的新兴药物治疗法。
J Dev Behav Pediatr. 2010 Sep;31(7):564-81. doi: 10.1097/DBP.0b013e3181ee3833.
4
The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.对于患有注意缺陷多动障碍的儿童和青少年，哌醋甲酯的益处和危害仍存在争议。
Clin Pharmacol Ther. 2018 Oct;104(4):606-609. doi: 10.1002/cpt.1149. Epub 2018 Jul 13.
5
Pathways to drug development for autism spectrum disorders.自闭症谱系障碍的药物研发途径。
Clin Pharmacol Ther. 2012 Feb;91(2):189-200. doi: 10.1038/clpt.2011.245. Epub 2011 Dec 28.
6
Subgroups in autism: are there behavioural phenotypes typical of underlying medical conditions?自闭症的亚组：是否存在潜在医学状况所特有的行为表型？
J Intellect Disabil Res. 1992 Jun;36 ( Pt 3):201-14. doi: 10.1111/j.1365-2788.1992.tb00508.x.
7
Early life exposure to air pollution particulate matter (PM) as risk factor for attention deficit/hyperactivity disorder (ADHD): Need for novel strategies for mechanisms and causalities.早期暴露于空气污染物（PM）作为注意缺陷多动障碍（ADHD）的风险因素：需要新的策略来研究其机制和因果关系。
Toxicol Appl Pharmacol. 2018 Sep 1;354:196-214. doi: 10.1016/j.taap.2018.03.015. Epub 2018 Mar 14.
8
Getting to Long-Term Effectiveness and Safety of Attention-deficit Hyperactivity Disorder Medications.达到注意缺陷多动障碍药物的长期有效性和安全性。
Clin Pharmacol Ther. 2018 Oct;104(4):610-612. doi: 10.1002/cpt.1137. Epub 2018 Aug 17.
9
A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.抗坏血酸与α-生育酚联合用于测试脆性X综合征有效性和安全性：一项II期随机安慰剂对照试验的研究方案
Trials. 2014 Sep 3;15:345. doi: 10.1186/1745-6215-15-345.
引用本文的文献
1
Treating Rett syndrome: from mouse models to human therapies.治疗雷特综合征：从小鼠模型到人类疗法。
Mamm Genome. 2019 Jun;30(5-6):90-110. doi: 10.1007/s00335-019-09793-5. Epub 2019 Feb 28.
2
From gene to treatment: supporting rare disease translational research through model systems.从基因到治疗：通过模型系统支持罕见病转化研究。
Dis Model Mech. 2019 Feb 22;12(2):dmm039271. doi: 10.1242/dmm.039271.
本文引用的文献
1
Impact of a five-dimensional framework on R&D productivity at AstraZeneca.阿斯利康五维框架对研发生产力的影响。
Nat Rev Drug Discov. 2018 Mar;17(3):167-181. doi: 10.1038/nrd.2017.244. Epub 2018 Jan 19.
2
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.神经发育障碍药物研发：脆性 X 综合征的经验教训。
Nat Rev Drug Discov. 2018 Apr;17(4):280-299. doi: 10.1038/nrd.2017.221. Epub 2017 Dec 8.
3
Neurobiologically-based treatments in Rett syndrome: opportunities and challenges.雷特综合征基于神经生物学的治疗方法：机遇与挑战。
Expert Opin Orphan Drugs. 2016 Oct 2;4(10):1043-1055. doi: 10.1080/21678707.2016.1229181. Epub 2016 Sep 10.
4
Rett Syndrome: Crossing the Threshold to Clinical Translation.雷特综合征：迈向临床转化的关键一步。
Trends Neurosci. 2016 Feb;39(2):100-113. doi: 10.1016/j.tins.2015.12.008.
5
Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders.自闭症及相关神经发育障碍的基因、神经回路与精准疗法
Science. 2015 Nov 20;350(6263). doi: 10.1126/science.aab3897. Epub 2015 Oct 15.
6
Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis.遗传疾病中自闭症谱系障碍现象学的患病率：一项系统综述和荟萃分析。
Lancet Psychiatry. 2015 Oct;2(10):909-16. doi: 10.1016/S2215-0366(15)00376-4. Epub 2015 Sep 1.
7
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.基因决定的智力残疾中的安慰剂反应：一项荟萃分析。
PLoS One. 2015 Jul 30;10(7):e0133316. doi: 10.1371/journal.pone.0133316. eCollection 2015.
8
Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.结节性硬化症：自闭症靶向治疗的新前沿。
Neurotherapeutics. 2015 Jul;12(3):572-83. doi: 10.1007/s13311-015-0359-5.
9
Everolimus alters white matter diffusion in tuberous sclerosis complex.依维莫司改变结节性硬化症患者的脑白质弥散。
Neurology. 2012 Feb 21;78(8):526-31. doi: 10.1212/WNL.0b013e318247ca8d. Epub 2012 Jan 18.
10
Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex.脑白质微观结构完整性的丧失与结节性硬化症的不良神经预后相关。
Acad Radiol. 2012 Jan;19(1):17-25. doi: 10.1016/j.acra.2011.08.016.
Zotero 插件